Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)
LUNGEVITY
1 other identifier
observational
1,000
1 country
46
Brief Summary
The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment. Participants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study. They will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2025
Longer than P75 for all trials
46 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 2, 2025
CompletedFirst Submitted
Initial submission to the registry
November 17, 2025
CompletedFirst Posted
Study publicly available on registry
November 21, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 31, 2031
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 31, 2031
April 27, 2026
April 1, 2026
5.6 years
November 17, 2025
April 24, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (7)
Baseline Clinical Characteristics
Metastatic Lung Cancer Long-Terms Responders clinical characteristics: baseline patient demographics, clinical and pathological characteristics (e.g. age, medical history, comorbidities, past history of cancer, smoking status, NSCLC or SCLC characteristics)
At Baseline visit, on a maximum period of 12 months.
Aix-Marseille-University (AMU) questionnaire
At inclusion, 6 and 12 months after inclusion and every year up to 5 years
EORTC QLQ-LC13
at inclusion, 6 and 12 months after inclusion and every year up to 5 years
Hospital Anxiety and Depression Scale (HAD)
at inclusion, 6 and 12 months after inclusion and every year up to 5 years
Treatment characteristics
Treatment characteristics are defined by the type of treatment, the numbers of cycle and the duration of treatment.
From date of first lung cancer treatment administration up to 5 years
Health status
Health status will be evaluated using Eastern Cooperative Oncology Group performance status (PS), and collecting data new diseases, cardiovascular, diabetes, second cancers
At Baseline visit and up to 5 years
Socio-demographic characteristics
Socio-demographic characteristics will be evaluated based on the following data: professional, socio-family and socio-economic characteristics, education, family status, potential professional exposure(s)
At Baseline visit and up to 5 years
Secondary Outcomes (2)
Progression free survival (PFS)
From date of first lung cancer treatment administration up to 5 years
Overall Survival (OS)
From date of first lung cancer treatment initiation up to 5 years
Study Arms (1)
Long-Terms Responders in metastatic Lung Cancer
Long-term responders defined as patients alive for three years after diagnosis of metastatic Lung cancer (NSCLC and SCLC) and not receiving cytotoxic chemotherapy at the time of inclusion.
Interventions
The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to depression (total D), giving two scores (maximum score for each = 21).
The EORTC QLQ-LC13: a 13-item lung cancer-specific questionnaire module supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (cough, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.
Data analysis will be firstly descriptive in order to report on the quality of life of respondents. Then, in a second stage, the factors associated with quality of life will be analyzed using linear or logistic regression models depending on the nature of the variable of interest.
Eligibility Criteria
Patients will be recruited by GFPC centers which is a large French network of hospitals and clinics particularly active in pneumology and thoracic oncology centers participating in clinical research. The principal investigator in each center will identify consecutive patients eligible for inclusion. Patients will be asked to confirm their consent for data collection.
You may qualify if:
- Patient over 18 years old
- Patients covered by the French National Health Insurance program or with thirdparty-payer health insurance
You may not qualify if:
- Difficulties for understanding French
- Patients undergoing treatment with cytotoxic chemotherapy
- Patients under legal guardianship, under curatorship or tutorship
- Insufficient cognitive capacity to answer questions
- Inability to obtain data collection (lost to follow-up, patient's refusal for data collection)
- Patients refusing the collection of their data (an information sheet will be provided)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (46)
CH du Pays d Aix
Aix-en-Provence, 13616, France
CHU Angers
Angers, 49033, France
Hôpital Henri Duffaut
Avignon, 84000, France
CH Bastia
Bastia, 20200, France
APHP Hôpital Avicennes
Bobigny, 93000, France
CHU Morvan
Brest, 29200, France
Hôpital Louis Pradel
Bron, 69500, France
Pneumologie Centre François Baclesse
Caen, 14000, France
Centre Hospitalier du Cotentin
Cherbourg, 50102, France
CHU Hôpital Montpied
Clermont-Ferrand, 63000, France
Oncologie CLCC Jean Perrin
Clermont-Ferrand, 63000, France
Pneumologie Hospices Civils de Colmar
Colmar, 68024, France
Pneumologie Centre Hospitalier Intercommunal de Créteil
Créteil, 94010, France
Centre Hospitalier d'Elbeuf - Pneumologie
Elbeuf, 76503, France
CH Eure-Seine
Évreux, 27015, France
Grand Hôpital de l'Est Francilien - Site Marne la Vallée
Jossigny, 77600, France
Centre Hospitalier Les Oudairies
La Roche-sur-Yon, 85000, France
CH La Rochelle
La Rochelle, 17000, France
Hôpital Robert Boulin
Libourne, 33505, France
Hôpital de la Vallée
Longjumeau, 91160, France
Hôpital du Scorff
Lorient, 56100, France
Pneumologie Hôpital privé Jean Mermoz
Lyon, 69085, France
Centre Léon Bérard
Lyon, 69373, France
Hôpital Européen
Marseille, 130003, France
Hôpital Nord - Oncologie Thoracique
Marseille, France
GHEF Site de Meaux
Meaux, 77100, France
CHRU de Nancy
Nancy, 54000, France
CHU Nantes
Nantes, 44000, France
Pneumologie Hôpital Cochin
Paris, 75014, France
Hôpital Tenon
Paris, 75020, France
Hôpital La Pitié-Salpêtrière
Paris, 75651, France
Pneumologie Centre Hospitalier
Pau, 64000, France
Centre Catalan d'Oncologie
Perpignan, 66000, France
CHU Reims Hôpital Maison Blanche
Reims, 51000, France
CHU Hôpital Ponchailloux
Rennes, 35033, France
Hôpital Charles Nicolle
Rouen, 76031, France
Hôpital Privé de la Loire
Saint-Etienne, 42000, France
Pneumologie CHU St Etienne
Saint-Etienne, 42270, France
CH des Vallées de l'Ariège
Saint-Jean-de-Verges, 09000, France
CHU La Réunion Site Sud
Saint-Pierre, 97410, France
CHU La Réunion Site Sud
Saint-Pierre, 97410, France
CH de Saint Malo
St-Malo, 35000, France
Hôpital d'Instruction des Armées Saint-Anne
Toulon, 83041, France
Hôpital Larrey
Toulouse, 31059, France
Oncologie CH Bretagne-Atlantique
Vannes, 56000, France
Centre Hospitalier de Villefranche sur Saone
Villefranche-sur-Saône, 69655, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lionel FALCHERO
GFPC
- PRINCIPAL INVESTIGATOR
Laurence BIGAY-GAME
GFPC
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 17, 2025
First Posted
November 21, 2025
Study Start
July 2, 2025
Primary Completion (Estimated)
January 31, 2031
Study Completion (Estimated)
January 31, 2031
Last Updated
April 27, 2026
Record last verified: 2026-04